Request Demo
Last update 12 Feb 2026
Ipratropium Bromide
Last update 12 Feb 2026
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Ipratropium bromide (USP), Ipratropium Bromide Hydrate, Ipratropium bromide hydrate (JP17) + [9] |
Target |
Action antagonists |
Mechanism mAChRs antagonists(Muscarinic acetylcholine receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (25 Oct 1980), |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC20H32BrNO4 |
InChIKeyKEWHKYJURDBRMN-ZEODDXGYSA-M |
CAS Registry66985-17-9 |
Related
119
Clinical Trials associated with Ipratropium BromideNCT07394036
The Effect of Ipratropium Bromide on Exercise-Induced Laryngeal Obstruction (EILO) in Pediatric Patients
ITMCTR2026000018
Analysis of Efficacy and Safety of Bailing Capsules Combined with Ipratropium Bromide for COPD with Cor Pulmonale
CTR20252731
单中心、随机、开放、两序列、两周期交叉设计评估中国健康研究参与者非炭阻、空腹状态下经口吸入异丙托溴铵吸入气雾剂的生物等效性试验
[Translation] A single-center, randomized, open-label, two-sequence, two-period crossover design to evaluate the bioequivalence of oral ipratropium bromide inhalation aerosol in participants of the China Health Study in the non-carbuncle-free, fasting state
100 Clinical Results associated with Ipratropium Bromide
Login to view more data
100 Translational Medicine associated with Ipratropium Bromide
Login to view more data
100 Patents (Medical) associated with Ipratropium Bromide
Login to view more data
2,103
Literatures (Medical) associated with Ipratropium Bromide01 Apr 2026Intensive and Critical Care Nursing
Practice of nebulization in intensive care unit patients receiving invasive ventilation – A nationwide survey
Article
Author: Dongelmans, Dave A ; Stilma, Willemke ; Esmeijer, Andrea A ; Visser, Annelies ; Paulus, Frederique ; Mugge, Sarah F C
BACKGROUND:
Nebulization with mucolytic and bronchodilator agents is frequently applied in Intensive Care Units (ICUs) for invasively ventilated patients, despite limited evidence for clinical benefit and potential risks associated with routine use. Understanding current practice and rationale behind nebulization is essential to targeted de-implementation strategies.
METHODS:
We conducted a nationwide, cross-sectional telephone survey among ICU healthcare professionals in the Netherlands. The survey addressed nebulization practices for mucolytics and bronchodilators, including agents used, administration strategy, clinical indications, evaluation strategies, and local protocols. Open-ended questions explored underlying clinical reasoning and factors influencing nebulization practices.
RESULTS:
Representatives from 54 of 71 Dutch ICUs (76%) participated. Most respondents were ventilation practitioners (72%, 39/54), supplemented by ICU nurses and intensivists. Nebulization with mucolytics was reported in 47 ICUs (87%) ICUs and with bronchodilators in all ICUs. On-demand nebulization predominated (91.5%, 43/47 for mucolytics; 83.3%, 45/54 for bronchodilators). Thick secretions were the main indication for mucolytics, whereas obstructive pulmonary disease and bronchospasm were leading indications for bronchodilators. Acetylcysteine and salbutamol/ipratropium were most frequently used. Local protocols were present in 41 (76%) ICUs. Active humidification was commonly applied on indication, particularly in prolonged ventilation. Responses to open-ended questions revealed that, beyond clinical triggers, nebulization decisions were frequently shaped by personal preference, habitual practice, and organizational context, rather than by evidence-based reasoning.
CONCLUSION:
Nebulization in Dutch ICUs is predominantly on-demand but practice remains variable and partly driven by ingrained habits instead of evidence. Non-indicated nebulization persists and represents potential low-value care.
IMPLICATIONS FOR CLINICAL PRACTICE:
This nationwide survey demonstrates that nebulization practices in Dutch ICUs remain highly variable, often driven by non-standardized protocols and subjective interpretation of indications rather than evidence. To promote more consistent and evidence-based care, implementing a practical decision-support tool could guide clinicians toward indication-based nebulization and support de-implementation of routine, non-indicated use.
01 Feb 2026IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA
Medical Management of Rhinitis
Review
Author: Peters, Anju ; Shaker, Marcus ; Li, Sylvia
Pharmacologic treatment of rhinitis includes intranasal and oral therapies targeting inflammation and histamine activity. Intranasal corticosteroids and non-sedating antihistamines are first-line due to high efficacy and safety. Intranasal ipratropium, cromolyn, and decongestants offer symptom-specific relief. Oral medications such as antihistamines, leukotriene receptor antagonists, decongestants, and corticosteroids, vary in efficacy and side effects. Emerging therapies like biologics and CRTH2/DPP-4 inhibitors show promise in clinical and preclinical studies.
01 Jan 2026The journal of allergy and clinical immunology. Global
Depression in children with asthma: Testing a cholinergically mediated “endotype”
Article
Author: Wood, Beatrice L ; Miller, Bruce D ; Humayun, Quratulain ; Lam, Weyman ; Lehman, Heather K
Background:
Asthma is not a single uniform disease; instead, it comprises various disease sub entities, or "endotypes," with different etiologies and pathophysiologies. As asthma endotypes are discerned, individuals with asthma can be matched with optimal therapies for their specific asthma subtype. Depression is common in persons with asthma and associated with increased asthma-related morbidity and mortality. Depression in child asthma is associated with a predominance of parasympathetic/cholinergic activation over sympathetic activation. Cholinergic activity mediates airway smooth muscle constriction and has effects on airway inflammatory cells and mucus-secreting goblet cells.
Objective:
The goal of the current study was to examine whether children with asthma who have more depressive symptoms have cholinergically mediated disease that is differentially responsive to short-acting anticholinergic therapy.
Methods:
A total of 39 children with asthma (aged 7-17 years) and baseline obstruction on spirometry were evaluated for depressive symptoms by using the Children's Depression Inventory. Spirometry was used to evaluate the children for improvement in airway function following treatment with a short-acting anticholinergic medication. Inflammation was assessed by determining fractional exhaled nitric oxide levels and peripheral blood eosinophil counts, and atopic status was assessed by skin prick testing and measurement of total serum IgE level.
Results:
There was a statistically significant positive correlation between depressive symptoms and increase in FEV1 percent predicted value in response to ipratropium administration (rs = 0.344; P = .032).
Conclusion:
Higher depressive symptom scores are associated with increased airway responsiveness to inhaled ipratropium in children with asthma and active airway obstruction. These findings suggest the potential for definition of an endotype of asthma with comorbid depression that may benefit from anticholinergic asthma therapies.
20
News (Medical) associated with Ipratropium Bromide
05 Jul 2025
Drug Approval
100 Deals associated with Ipratropium Bromide
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D02212 | Ipratropium Bromide |
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Rhinitis, Allergic, Seasonal | United States | 27 Oct 2000 | |
| Common Cold | United States | 20 Oct 1995 | |
| Rhinitis | United States | 20 Oct 1995 | |
| Bronchial Spasm | United States | 29 Sep 1993 | |
| Pulmonary Disease, Chronic Obstructive | United States | 29 Sep 1993 | |
| Asthma | Japan | 25 Oct 1980 | |
| Bronchitis, Chronic | Japan | 25 Oct 1980 | |
| Pulmonary Emphysema | Japan | 25 Oct 1980 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Dyspnea | Clinical | Canada | 01 Oct 2008 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | 141 | (Levalbuterol) | swdetvfgfh = bujghzeceo kriqmifdfi (aqdrxnvdwt, zmwqhlhbaf - qalrctuvln) View more | - | 16 May 2022 | ||
(Levalbuterol Plus Ipratropium) | swdetvfgfh = mntysjfwih kriqmifdfi (aqdrxnvdwt, inqupunrsq - utdtbnosvg) View more | ||||||
Phase 4 | 40 | inytqwxdwf(ywvxnccqmx) = ddibgmovvy tgzchnsjlm (ihpqlujgdg, 25.2) View more | - | 10 Jun 2021 | |||
(Dry Powder Inhaler) | inytqwxdwf(ywvxnccqmx) = xcoaxxigzi tgzchnsjlm (ihpqlujgdg, 19.8) View more | ||||||
Phase 4 | 20 | Placebo (Placebo) | ynphhrnkdy(cbambpeszj) = cgwxbzxyju bpsaxwoflp (xzobkkkekc, idhqwtmlqk - ludauhqjtt) View more | - | 05 Jun 2020 | ||
(Ipratropium Bromide) | ynphhrnkdy(cbambpeszj) = mvnkacflpa bpsaxwoflp (xzobkkkekc, ytakvvsane - jeeaavohgw) View more | ||||||
Phase 4 | 20 | (Ipratropium) | tqjgnxqtcm(vztezqyetx) = amyicbeyyf vyjehfqshc (qqbssznqgj, wibriecgax - wudpvvgybl) View more | - | 12 Oct 2016 | ||
(Theophylline) | tqjgnxqtcm(vztezqyetx) = hgbrofqdyl vyjehfqshc (qqbssznqgj, exsodjoxay - bnesswrbws) View more | ||||||
Phase 4 | 192 | placebo | eoxlzcefkv(vhakacqozp) = tgblouhacq cbyoaihpbg (xwphjcmdjz, 29.35) View more | - | 12 Sep 2016 | ||
Phase 3 | 15 | (Albuterol-sulphate) | hkkzqrfjil(ifozgmisdq) = jxccqpfjrh utpeugrpwh (nfptqngzar, 13.6) View more | - | 02 Jun 2016 | ||
(Ipratropium-bromide (Atrovent ®)) | hkkzqrfjil(ifozgmisdq) = qdpvabnbtn utpeugrpwh (nfptqngzar, 10.9) View more | ||||||
Not Applicable | - | Salbutamol, Prednisolone, and Ipratropium Bromide | zlbmhupmnp(somdfvxcig) = fltyspnefu lppsnvmqan (mcoofqsfwd ) View more | - | 01 Feb 2015 | ||
Salbutamol and Prednisolone | zlbmhupmnp(somdfvxcig) = qpogtrlosg lppsnvmqan (mcoofqsfwd ) View more | ||||||
Phase 4 | 581 | (Symbicort Turbuhaler + Ipratropium + Theophylline SR) | scifjgyeqt(bfduizxrml) = ugbahzpzyl ekpuvavugh (kmsihwpucf, kxyctwncbi - ccvfjvzwvm) View more | - | 26 Aug 2014 | ||
(Ipratropium + Theophylline SR) | scifjgyeqt(bfduizxrml) = qxljuwmlwl ekpuvavugh (kmsihwpucf, imtraiedhv - xyrmlhwpcb) View more | ||||||
Phase 4 | 56 | (Albuterol/Salbutamol Followed by Ipratropium) | gtfpvdsgma(qaabvyccpd) = bozrgmwviz pzfmedacbl (qxdyeamftu, 0.0394) View more | - | 25 Dec 2013 | ||
(Ipratropium Followed by Albuterol/Salbutamol) | gtfpvdsgma(qaabvyccpd) = gbesxwolju pzfmedacbl (qxdyeamftu, 0.0372) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free